Anacetrapib

From Anvita Health Wiki

Contents 1 Introduction 2 Indications 3 Dosage 4 Mechanism-of-action 5 Clinical-trials 6 More General Terms 7 References

Introduction

• Experimental agent. Drug in phase 1 trials.

Indications

• dyslipidemia, hypercholesterolemia

Dosage

• 100 mg QD
• 10-300 mg PO QHS

Mechanism-of-action

• inhibition of cholesteryl ester transfer protein ( CETP)
• increases HDL 130% (300 mg)
• decrease LDL 40% (300 mg)
• no change in blood pressure

Clinical-trials

• mean LDL cholesterol decrease from 81 to 45 mg/dL vs 82 to 77 mg/dL with placebo
• mean HDL cholesterol increase from 41 to 101 mg/dL vs 40 to 46 mg/dL with placebo
• no benefit in terms of cardiovascular events or mortality within trial window of 18 months

More General Terms

• anti-hyperlipidemic agent

References

1. Krishna R et al, Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: Two double-blind, randomised placebo-controlled phast I studies. Lancet 2007, 370:1907 PMID: [1]
2. Physician' First Watch, Nov 18, 2010 Massachussetts Medical Society [2]
   - Cannon CP et al Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease N Engl J Med November 17, 2010 <PubMed> PMID: [3] <Internet> [4]

anacetrapib